The successful inspection comes following Axxess Pharma’s most recent letter of intent (LOI) to acquire a Canada-based pharmaceutical manufacturer.
Axxess Pharma’s facility is roughly 22,000sqft and manufactures pharmaceuticals, neutroceuticals and dermatologicals.
Axxess Pharma said that it would continue the distribution of its own line of pharmaceuticals from its Markham location.
Gerald Sequeira, president and CEO of Axxess Pharma, said: “Our facilities are now in place to process and manufacture all orders worldwide. In recent months we have signed exclusive license agreements in Latin America, Africa, Middle East and Canada with non-exclusive sales in the US and various other countries.
“This is one more sign that we are focused on continuing to expand our operations across Canada and gain market share.”